Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.58 billion for the third quarter ended July 31, 2024, a decline of 5.6% reported and 4.4% core(1) compared to the third quarter of 2023.
Siemens Healthineers AG today announces its results for the third quarter of fiscal year 2024 ended June 30, 2024.
Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2024.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal 2024, which ended December 31, 2023.
Revvity, Inc. (NYSE: RVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023.
Siemens Healthineers AG today announces its results for the first quarter of fiscal year 2024 ended December 31, 2023.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023.
Just as users around the world are surely strapping on new Fitbits with an aim of tackling health-focused New Year’s resolutions, so too is Fitbit itself kicking off 2024 with its sights set on a new goal.
US-based Calibre Scientific has acquired German MoBiTech for an undisclosed amount to bolster its portfolio of diagnostic services.
✔ All (161)
✔ Press release (1)
✔ Industry news (160)
Don’t miss important updates about the show and the in vitro diagnostic industry.
Sign-up for our newsletter today.
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.